The long-standing duopoly of the weight-loss drug market faced its most significant challenge yet this week as Hims & Hers Health, Inc. (NYSE: HIMS) announced a breakthrough $49 compounded oral semaglutide pill. The move, aimed directly at the market share of pharmaceutical titans Eli Lilly and Company (NYSE: LLY) and Novo
In a dramatic week for the pharmaceutical sector, a stark rift has opened between the two undisputed titans of the weight-loss drug market. On February 4, 2026, Eli Lilly (NYSE:LLY) reported a staggering 45% surge in full-year 2025 revenue, propelled by the insatiable global demand for its blockbuster treatments,
Volatility cuts both ways - while it creates opportunities, it also increases risk, making sharp declines just as likely as big gains.
This unpredictability can shake out even the most experienced investors.
Shareholders of Hims & Hers Health would probably like to forget the past six months even happened. The stock dropped 57.1% and now trades at $27.15. This may have investors wondering how to approach the situation.
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Shareholders who bet on the industry have been rewarded lately
as healthcare stocks have returned 17.4% over the past six months, topping the S&P 500 by 7.8 percentage points.
Netflix may be forced to offer all cash for WBD if the cable assets being spun off don't have the value Netflix thought they did. But is that something Netflix will do, and what are the risks?
Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 2.2% in the morning session after Morgan Stanley reiterated its Equalweight rating but voiced concerns about the company's slowing growth and increasing competition.
"You get what you pay for" often applies to expensive stocks with best-in-class business models and execution.
While their quality can sometimes justify the premium, they typically experience elevated volatility during market downturns when expectations change.
